Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PUFFIN: Pertuzumab in Chinese patients with HER2+ metastatic breast cancer
NCT02896855Phase 3Completed
- Sponsor
- Roche
- Start
- Sep 2016
- Primary completion
- Jun 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in HER2-positive metastatic breast cancer comparing Placebo + Trastuzumab + Docetaxel with Pertuzumab + Trastuzumab + Docetaxel (2 arms). Primary endpoints: Progression-Free Survival and Event-Free for Progression-Free Survival at 3 years. Started Sep 2016; status: completed.
02
Drugs
pertuzumab
03
Conditions
HER2-positive metastatic breast cancer
Beyond the preview
Go deeper on NCT02896855.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02896855.